The inclusion of SARS-CoV-2 in the BIOFIRE® RP2.1 panel allows healthcare providers to quickly identify patients with common respiratory pathogens, as well as those with COVID-19, using one ...

Regulatory News: bioMérieux (Paris:BIM), a world leader in the field of in vitro diagnostics, today announced that the BIOFIRE Respiratory Panel 2.1 plus (RP2.1plus) is CE marked. The ...

The BD MAX Respiratory Viral Panel detected and differentiated between influenza A and B respiratory syncytial virus and SARS-CoV-2. The panel requires less than 1.5 minutes hands-on time per sample.

The BD MAX Respiratory Viral Panel uses a single nasal or nasopharyngeal swab sample to determine if a patient has COVID-19, the flu or RSV. – BD. Patients wondering whether they have COVID-19 ...

Rather than running multiple tests on samples, the PKamp Respiratory SARS-CoV-2 RT-PCR Panel is designed to conserve resources by testing a single nasopharyngeal, oropharyngeal or nasal swab sample ...

Importantly, based on viral load distribution in individuals that were tested for the first time in this study, approximately 20% of those infected with SARS-CoV-2 would be missed if sampled using ...

(RTTNews) - Luminex Corp. (LMNX) announced Wednesday that it has submitted an Emergency Use Authorization or EUA request to the FDA for a new expanded version of its NxTAG Respiratory Pathogen ...

QIAGEN N.V. QGEN recently secured FDA clearance for the QIAstat-Dx Respiratory Panel Plus syndromic test. Previously authorized under the FDA Emergency Use Authorization (“EUA”) as the QIAstat ...

Bronchoalveolar-lavage (BAL) fluid (Panel A) and nasal swab (Panel B) specimens were obtained on days 1, 2, 4, and 7 after challenge, where applicable, and viral replication was assessed by ...